Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
370
Trial Sponsor
Clinical Trial Start Date
2006
0Primary Completion Date
2012
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Interventional Trial Phase
Phase 20
Official Name
Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma0
Last Updated
August 26, 2013
0Masking Type
None (Open Label)0
Study summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of lymphoma by blocking blood flow to the cancer. Giving fludarabine and cyclophosphamide together with thalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide together with thalidomide works in treating patients with angioimmunoblastic T-cell lymphoma.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
